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Aim: The aim of this study was to test the hypothesis that initial pain intensity is not a pre-
dictive factor of poor opioid response in advanced cancer patients, as suggested by a recent
work.
Methods: A secondary analysis of one-hundred-sixty-seven patients referred for treatment
of cancer-related pain was conducted. Pain intensity at admission was recorded and
patients were divided in three categories of pain intensity: mild, moderate and severe.
Patients were offered a treatment with opioid dose titration, according to department pol-
icy. Data regarding opioid doses and pain intensity were collected after dose titration was
completed. Four levels of opioid response were considered: (a) good pain control, with min-
imal opioid escalation and without relevant adverse effects; (b) good pain control requiring
more aggressive opioid escalation, for example doubling the doses in four days; (c) ade-
quate pain control associated with the occurrence of adverse effects; (d) poor pain control
with adverse effects.
Results: Seventy-six, forty-four, forty-one and six patients showed a response a, b, c, and d,
respectively. No correlation between baseline pain intensity categories and opioid response
was found. Patients with response ‘b’ and ‘d’ showed higher values of OEI mg.
Conclusion: Baseline pain intensity does not predict the outcome after an appropriate opi-
oid titration. It is likely that non-homogeneous pain treatment would have biased the out-
come of a previous work.
 2011 Elsevier Ltd. All rights reserved.1. Introduction istics of disease, pain and patients.1 The intention of a cancerThe heterogeneity and complexity of patients with cancer
pain have represented a relevant challenge for researchers
in an attempt of grouping patients according to the character-er Ltd. All rights reserved
and Palliative Care Unit, L
10.
alenanet.it (S. Mercadantpain classification has been to improve pain management
and to predict the likelihood of successful pain treatment,
possibly identifying cancer patients who are less likely to re-
spond to standard treatment. The Edmonton Staging System.
a Maddalena Cancer Center, Via San Lorenzo 312, 90146 Palermo,
e).
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researchers to speak a common language and to make mean-
ingful generalisation from the results of clinical trials.2 Candi-
date variables to assess pain prognosis from different
dimensions were analysed, and the prognostic factors were
summarised in three prognostic stages. The accuracy of ESS
was assessed in subsequent multicentre trials, as the original
staging system demonstrated some weakness. In a new ver-
sion of ESS (revised ESS and rESS), a different construct was
hypothesised, according to which patients with less problem-
atic pain features would require a shorter time to achieve sta-
ble pain control, require less complicated analgesic regimens,
are more responsive to opioid therapy, and use lower opioid
doses,3 accomplishing a more relative concept of opioid re-
sponse. This classification was based on two stages, in which
the original intermediate group was combined with the poor
prognosis group. rESS had a better predictive value and a
moderate to high inter-rater reliability. However, 60–67% of
patients still achieved stable pain control, regardless of pain
classification.
In a recent secondary analysis, other than previous factors
examined including younger age, neuropathic pain, incident
pain, psychological distress, baseline pain intensity have
been found to have longer times to stable pain control, sug-
gesting to incorporate this factor in a new staging system.1
This data were confirmed in an international multicentre val-
idation study. Initial pain intensity was associated with more
days to achieve stable pain control.4 High level of pain inten-
sity, however, does not seem clinically an intrinsic factor, as
may possibly depend on several factors, for example previous
undertreatment, which per se could be resolved in a simple
way and could not influence the prognosis. It could be argued
that patients recruited in multicentre studies may receive dif-
ferent or less intensive treatment, which may influence the
outcome.
The aim of this study was to clarify the role of pain inten-
sity at admission as a predictive factor of poor pain control. To
test this hypothesis data of advanced cancer patients as-
sessed in a study of opioid response were reviewed in a sec-
ondary analysis.5 This group of patients were treated
homogeneously, according to a clear protocol in acute pallia-
tive care units.2. Patients and methods
This was a secondary analysis of a prospectively collected
sample of one-hundred-sixty-seven patients referred for
treatment of cancer-related pain to two acute pain relief
and supportive care units during 18 month period. The ori-
ginal methods are described elsewhere.5 Before starting the
treatment (T0) pain intensity in the past 24 h (average pain)
was measured by using a numerical scale from 0 to 10,
choosing a number from 0 (no pain) to 10 (the worst pain
imaginable). Patients were grouped in the ranges proposed
by Fainsinger et al.1: mild, 0–3; moderate, 4–6; and severe,
7–10. Patients were offered a treatment with opioid dose
titration, balancing analgesia and adverse effects, eventually
supported by symptomatic drugs, according to department
policy and routine protocols in the units. The choice of opi-oids was individualised according to previous exposure and
response, and tailored opioid titration was performed
according to the pain intensity and patients’ needs, eventu-
ally changing the route of administration, for example in
patients with nausea and vomiting which precluded the oral
route. An unfavourable opioid response, with a prevalence
of adverse effects over analgesia despite supportive treat-
ment, was followed by opioid switching, using starting con-
version ratios previously described,6 with subsequent doses
changed according to the clinical response. Data regarding
opioid doses and symptom intensity were then repeated
after dose titration was completed and opioid doses were
stable or after a week (T1). Opioid dose stabilisation was
considered as the planned daily dose requiring no more
than two rescue doses as needed. Data were expressed in
oral morphine equivalents.
At time of stabilisation (T1), the opioid response was
clinically graded as follows: (a) good pain control (3 or less
on a numerical scale 0–10) with minimal increases in opioid
doses (less than doubling the doses) and without relevant
adverse effects; (b) good pain control requiring more
aggressive opioid escalation without adverse effects, for
example doubling the doses in four days; (c) adequate pain
control associated with the occurrence of adverse effects
(intensity 2–3); (d) poor pain control with adverse effects.
The opioid escalation index (OEI) was calculated as a per-
centage from the initial dose at T0–T1 (after a week),
according to the following formula: OEI%: [(x ) y)/y]/
days · 100, where x is dose at stabilisation and y is the dose
at admission. OEI in mg was calculated with the following
formula: (x ) y)/days, as oral morphine equivalents. This va-
lue has been used to express the need of opioid escalation
in cancer patients.72.1. Statistical analysis
A power analysis indicate that a sample size of 25 patients per
group would allow the detection of a 20% difference in pain
intensity score (P < 0.05, power = 0.8). This computation as-
sumes that the mean difference is 0.20 with a 95% confidence
interval of 0.07–0.33 and the common within-group standard
deviation of 0.28.
Frequency analysis was performed with chi-square test.
The chi-square for linear trend test was used to evaluate
the different opioid response in the three pain intensity cate-
gories. A sample size of 30 patients for group was calculated
to detect approximately a 20% effect size for individual items
with 80% power at a significance level of P < 0.05.
The paired Wilcoxon signed-rank test was used to com-
pare pain intensity scores in the different treatment time.
The one-way analysis of variance (ANOVA) and Kruskal–
Wallis test were used for parametric and non-parametric
analysis, respectively, to evaluate differences between the
groups. Spearman’s rho correlation was used to test for a
trend between PI and opioid response and opioid escalation
indexes. All P values were two-sided and P values less than
0.05 were considered to indicate statistical significance.
Data were analysed by the EpiInfo software (version 6.0,
Centres for Disease Control and Prevention, Atlanta, GA,
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cago, Il, USA).
3. Results
The characteristics of patients and the number of patients
with mild, moderate and severe pain at admission (and after
titration) are described in Table 1. One-hundred-three pa-
tients were males. The mean age was 65.7, 65.9 and 64.6
and mean Karnofsky status was 49.6, 52.5 and 55.2 in the
three pain intensity categories, respectively. No differences
in age, gender and Karnofsky status were found. The mean
baseline pain intensity in the three categories of pain inten-
sity was 2.3 (1.1), 5.2 (0.7) and 8.2 (1.1), respectively. The
mean pain intensity at stabilisation was 1.9 (1.2), 1.9 (1.3)
and 2.8 (2.0), respectively. Opioid titration significantly de-
creased pain intensity in the three categories of baseline
pain intensity, particularly in patients with severe pain (Ta-
ble 1). The mean time to reach dose stabilisation (T1) was
2.8 days (range 1–6). No statistical differences between pain
categories were observed (2.2, 3 and 3.4 days, respectively).
The pain intensity at T1 was correlated to baseline pain
intensity (P = 0.002).
Data regarding pain intensity categories, OEI and opioid re-
sponse after opioid titration are reported in Tables 2 and 3.
Only six patients had a response ‘d’ (poor pain control and ad-
verse effects) and were not considered for eventual compari-
son. No differences in OEI in the three pain level categories
were found.
The association between baseline pain intensity and opi-
oid response was significant (P = 0.007). No statistical differ-
ences in the number of patients with each opioid response
group were found amongst patients with different baseline
pain intensities (linear trend test; Table 2).
No correlation between baseline pain intensity and opioid
response (Spearman’s rho correlation coefficient 0.023; 95%
CI = )0.129 to 0.175, P = 0.765) was found, as well as between
baseline pain intensity groups and opioid response (Spear-
man’s rho correlation coefficient 0.070; 95% CI = )0.084 to
0.220, P = 0.373).
Data regarding the relationship between OEI and opioid re-
sponses are reported in Table 3. OEI was significantly associ-Table 1 – Characteristics of patients and data regarding pain ca
Mild pain
n = 28
Age mean (±SD) 65.7 (12.2)
Gender (M/F) 21/7
Karnofsky mean (±SD) 49.6 (6.0)
Primary tumour
Genitourinary 6 (21.4%)
Gastrointestinal 8 (28.6%)
Breast 4 (14.4%)
Lung 5 (17.8%)
Other 5 (17.8%)
Baseline pain intensity mean (±SD) 2.3 (1.1)
Pain intensity after titration mean (±SD) 1.9 (1.2)
*Univariate analysis of variance (ANOVA); ^Chi square testated with response ‘b’ (good pain control requiring more
aggressive opioid escalation), other than with response ‘d’
(poor pain control with adverse effects).
4. Discussion
Pain intensity at time of assessment has been recently indi-
cated as a negative prognostic factor. Pain intensity was asso-
ciated with a longer time to achieve stable pain control, high
final opioid doses, and more complicated analgesic regimens.1
Our hypothesis was that pain intensity ‘per se’ cannot be con-
sidered to be predictive of a poor analgesic response, as it often
depends on referral characteristics, for example treatment
behaviour on behalf of previous teams or GPs, rather than on
pain/patient characteristics. The reasons rely on the clinical
experience of patients who are often undertreated at referral
(and so present high pain intensity and receive inadequate
therapy) and then respond to adequate changes of therapy,
in some case just a timely increase in opioid doses. In this
study, patients with different baseline pain intensities did
not differ in opioid response after appropriate opioid titration.
The frequency comparison between baseline pain inten-
sity and opioid response was significant (P = 0.007), probably
because patients with moderate to severe pain were more
likely to produce a response ‘b’ (that is patients having good
pain control but requiring more aggressive opioid escalation).
This result exactly reflects our expectation regarding patients
who are undertreated and require an increase in opioid doses
which, however, cannot be considered a problematic issue.
However, different from Fainsinger’s findings, this did not re-
sulted in a more complex issue, giving that patients obtained
adequate pain relief within about three days.
In another trial assessing pain prognostic factors, no fac-
tors were identified in a three weeks study, unless for worst
pain severity after one week. Several surveys suggest that
one week is adequate to assess an analgesic treatment. Most
patients achieved pain relief >80% by week one, with a med-
ian pain relief of 40% after one day, doubling the dose of oral
morphine equivalents.8,9 Paradoxically, patients with highest
pain scores were more likely to perceive better pain relief. In
another study of one week duration, no single factor able to
predict treatment outcome was identified.10tegories at baseline and after titration.
Moderate pain
n = 98
Severe pain
n = 42
P
65.9 (11.5) 64.6 (10.9) 0.825*
61/37 21/21 0.102^
52.5 (9.9) 55.2 (10.4) 0.056*
26 (26.5%) 6 (14.3%)
22 (22.4%) 16 (38.0%)
6 (6.1%) 7 (16.7%)
15 (15.4%) 6 (14.3%)
29 (29.6%) 7 (16.7%)
5.2 (0.7) 8.2 (1.1)
1.9 (1.3) 2.8 (2.0) 0.002*
Table 2 – OEI values and opioid response in patients with mild, moderate and severe pain.
Mild pain n = 28 Moderate pain n = 98 Severe pain n = 42 P
OEI% mean (±SD) 131 (297) 182 (560) 179 (278) 0.873a
OEI mg mean (±SD) 6.2 (16.1) 10.3 (20.9) 10.7 (19.1) 0.582a
Response ‘a’ N = 76 18 (64.2%) 40 (40.8%) 18 (42.8%) 0.007b
Response ‘b’ N = 44 1 (3.6%) 30 (30.6%) 13 (30.9%)
Response ‘c’ N = 41 8 (28.6%) 27 (27.6%) 6 (14.3%)
Response ‘d’ N = 6 1 (3.6%) 1 (1.0%) 4 (9.5%)
Pc 0.346c 0.667c 0.745c
Response (a) good pain control, with minimal opioid escalation and without relevant adverse effects; (b) good pain control requiring more
aggressive opioid escalation, for example doubling the doses in four days; (c) adequate pain control associated with the occurrence of adverse
effects; (d) poor pain control with adverse effects.
a Kruskal–Wallis statistic.
b Fisher exact test.
c Chi square for linear trend test.
Table 3 – OEI values and the different categories of opioid response.
Response ‘a’ N = 76 Response ‘b’ N = 44 Response ‘c’ N = 41 Response ‘d’ N = 6 P
OEI% mean (±SD) 144 (259) 139 (228) 264 (834) 203.8 (399) 0.378a
OEI mg mean (±SD) 6.4 (13.5) 15.3 (22.2) 8.2 (24.6) 21.4 (22.4) <0.0005a
a Kruskal–Wallis statistic.
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cannot be considered as an inevitable negative factor in pain
prognosis. One possible explanation for the different findings
of this study in respect to Fainsinger’s studies,1,4 would rely
on the method of titration and consequently the median
length of time to stable pain control, which is a reasonable
method reported in many studies of cancer pain. For exam-
ple, in these two studies, patients with mild pain achieved
pain control in a median of four-five days with final doses
of parenteral morphine equivalents of 12-25 mg/day. Patients
with moderate pain achieved stable pain control after a med-
ian of eight-ten days with final doses of 48–64 mg/day. Finally,
patients with severe pain required a median of thirteen-
twenty-two days with dose of 68–72 mg. In this study, the
mean time to achieve adequate pain control was 2.8 days,
suggesting that a more timely opioid titration can produce a
rapid pain control in an appropriate setting, annulling the po-
tential influence of initial pain intensity. Similar protocols
were used in the two units involved in the present study.
We can only suppose that different settings could have used
different procedures of opioid titration, or that no established
protocol was planned in multicentre studies performed in dif-
ferent centres.
In patients admitted to our acute palliative care unit, the
time to achieve opioid dose stabilisation was about two days,
with a decrease of pain intensity from 7.1 to 2.3 (on a numer-
ical scale 0–10), and an OEI% of 52.11 Similarly, when patients
changed their daily equianalgesic doses of parenteral mor-
phine from 133 mg to 213 mg, pain relief was achieved in
the majority of patients within a week.8 Other experiences re-
ported adequate pain control within 24–48 h, independently
of the initial pain intensity.12,13
This study also confirmed the real meaning of OEI, in the
context of the concept of opioid responsiveness introducedin early nineties.14 Of interest, the equivalent morphine doses
found in the Fainsinger’s studies1,4 were not particularly high
to justify such a slow titration. The need for opioid dose esca-
lation as a feature of a pain classification system for advanced
cancer patients has been assessed in a secondary analysis of
a subsample of 532 advanced cancer patients. There were no
significant associations between OEI% and age, neuropathic
pain, incident pain, psychological distress, or addictive
behaviour.15 This outcome was expected, as OEI alone is just
a tool able to monitor the opioid requirements for a deter-
mined period, rather than being an outcome itself. The ‘opi-
oid escalation index’ (OEI) is a dynamic tool useful to
describe a trend in opioid response, where multiple factors
can be identified. On the other hand such a factor, expressed
in the previous version of ESS as ‘tolerance’,16 had been al-
ready removed from the staging system. As expected, in this
study OEI was associated with a response ‘b’, that is good pain
control requiring more aggressive opioid escalation, exactly
reproducing the meaning of this tool, that is the therapeutic
effort to achieve a meaningful outcome. Of course, in patients
with the worse response (‘d’), opioid doses were escalated
unsuccessfully, as no positive outcome was achieved within
the selected time of one week. Only six patients (3.5%) were
considered unresponsive (response ‘d’) after one week, con-
firming the appropriateness of the opioid treatment. On the
other hand the low number of patients in this group cannot
allow to draw any specific conclusion from a statistical point
of view. Further studies with a large cohort of patients, ran-
domly selected for a subgroup analysis, should provide new
information on this issue.
This study may have some limitations. Firstly, it was a sec-
ondary analysis. However, data were analysed through a rig-
orous assessment of specific parameters in a context of a
prospective study. For the same reasons, this study did not
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as incident pain, psychological distress and alcoholism or
chemical coping.1–3 As the distribution of these risk factors
amongst the different groups in unknown, these findings
should be considered preliminary and more research needs
to be done on this important subject. Another limitation
may derive by a more specific response to opioids, rather than
to analgesic regimens also including adjuvant drugs acting as
co-analgesics, due to the original protocol. However, data pre-
sented in terms of time to achieve a response seem to be even
more effective with opioid titration alone than those
produced in the recent rESS versions, where pain intensity
was examined as a predictive factor for poor pain relief and
other analgesic regimens were allowed. Finally, different
approaches to titration, referral bias, different outcome mea-
sures and the small number of ‘non-responders’ may hide
some common aspects between apparently different results.
In conclusion, data from this study suggest that initial
pain intensity does not predict the outcome, whether an
appropriate opioid titration is provided. The meaning of base-
line pain intensity, the previous opioid therapy, and treatment
behaviour as predictive factors of an analgesic response
should be tested in studies with appropriate designs and sim-
ilar protocols in opioid treatment. The lack of a common, va-
lid, and homogeneously applied method for assessing therapy
results still remains a major problem in research and clinical
practice.
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